GB Jaissle, M Leitritz, F Gelisken, F … - Graefe's Archive for Clinical and Experimental …, 2009 - Springer Page 1. RETINAL DISORDERS One-year results after intravitreal bevacizumab therapy
for macular edema secondary to branch retinal vein occlusion ... Cited by 18 - Related articles - All 2 versions
EJ Chung, YT Hong, SC Lee, OW Kwon, HJ … - Graefe's Archive for Clinical and Experimental …, 2008 - Springer Abstract Purpose To evaluate the prognostic factors for visual outcome after
intravitreal bevacizumab injection to treat macular edema due to branch retinal
vein occlusion (BRVO). Methods Fifty eyes of 50 consecutive patients ... Cited by 11 - Related articles - All 3 versions
F Prager, S Michels, K Kriechbaum, M … - British Medical Journal, 2008 - bjo.bmj.com Online First articles must include the digital object identifier (DOIs) and date
of initial publication. establish publication priority; they are indexed by
PubMed from initial publication. Citations to may be posted when available ... Cited by 7 - Related articles - All 3 versions
F Prager, S Michels, K Kriechbaum, M … - British Journal of Ophthalmology, 2009 - bjo.bmj.com Methods: Twenty-nine consecutive eyes with macular oedema secondary to BRVO (21
eyes) or CRVO (eight eyes) were included in a prospective clinical trial. Eyes
were treated with three initial intravitreal bevacizumab injections of 1 mg ... Cited by 5 - Related articles - All 4 versions
M Funk, K Kriechbaum, F Prager, T Benesch, … - Investigative Ophthalmology & Visual Science, 2009 - ARVO METHODS. In a prospective clinical trial, 13 eyes of patients with CRVO (n = 5)
or BRVO (n = 8) were included. Bevacizumab was administered intravitreously at
baseline and months 1 and 2. Retreatments were given at monthly visits if ... Cited by 6 - Related articles - All 3 versions
PV Algvere, A Kvanta, S Seregard - Acta ophthalmologica, 2008 - ncbi.nlm.nih.gov 1: Acta Ophthalmol. 2008 Jun;86(4):352-5. Shall we use Avastin or Lucentis for
ocular neovascularization? Algvere PV, Kvanta A, Seregard S. ... Cited by 3 - Related articles - BL Direct - All 2 versions
- ►duanesolution.com TA Ciulla, PJ Rosenfeld - Current Opinion in Ophthalmology, 2009 - journals.lww.com Recent findings: Early studies of the anti-VEGF agents, pegaptanib sodium,
ranibizumab, bevacizumab, VEGF trap, and bevasiranib in the treatment of various
neovascular diseases (eg, diabetic macular edema, retinal vein occlusion, ... Cited by 2 - Related articles - All 6 versions
- ►prsjournal.com A Sakamoto, A Tsujikawa, M Ota, N Yamaike, … - Clinical & Experimental Ophthalmology, 2009 - pt.wkhealth.com Methods:: Thirty-one eyes of 31 patients with MO associated with RVO were
examined and then treated with an intravitreal injection of bevacizumab. Of
these 31 eyes, 22 showed complete resolution of the MO at 1 month after ... Cited by 1 - Related articles - All 5 versions
JB Gunther, MM Altaweel - Survey of Ophthalmology, 2009 - Elsevier The use of intravitreal bevacizumab (Avastin) has greatly expanded since its
introduction into ophthalmic care 3 years ago. A PubMed search on 1 August 2008
revealed 51 ocular disease processes that have been treated with ... Cited by 2 - Related articles - All 23 versions
